These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16128941)

  • 1. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
    Poynard T; Zoulim F; Ratziu V; Degos F; Imbert-Bismut F; Deny P; Landais P; El Hasnaoui A; Slama A; Blin P; Thibault V; Parvaz P; Munteanu M; Trepo C
    Am J Gastroenterol; 2005 Sep; 100(9):1970-80. PubMed ID: 16128941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Thabut D; Le Calvez S; Thibault V; Massard J; Munteanu M; Di Martino V; Ratziu V; Poynard T
    Am J Gastroenterol; 2006 Jun; 101(6):1260-7. PubMed ID: 16771947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
    El-Shabrawi MH; Mohsen NA; Sherif MM; El-Karaksy HM; Abou-Yosef H; El-Sayed HM; Riad H; Bahaa N; Isa M; El-Hennawy A
    Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):946-51. PubMed ID: 20110820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
    Alric L; Kamar N; Bonnet D; Danjoux M; Abravanel F; Lauwers-Cances V; Rostaing L
    Transpl Int; 2009 May; 22(5):568-73. PubMed ID: 19196449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
    Myers RP; Ratziu V; Imbert-Bismut F; Charlotte F; Poynard T;
    Am J Gastroenterol; 2002 Sep; 97(9):2419-25. PubMed ID: 12358267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
    Uyar C; Akcam FZ; Ciris M; Kaya O; Kockar C; Isler M
    Indian J Pathol Microbiol; 2010; 53(3):470-5. PubMed ID: 20699505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time?
    Thuluvath PJ; Krok KL
    Am J Gastroenterol; 2006 Jul; 101(7):1497-9. PubMed ID: 16863552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
    Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P
    J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
    Said Y; Salem M; Mouelhi L; Mekki H; Houissa F; Ben Rejeb M; Moussa A; Trabelsi S; Debbeche R; Bouzaidi S; Najjar T
    Tunis Med; 2010 Aug; 88(8):573-8. PubMed ID: 20711964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FibroTest-ActiTest as a non-invasive marker of liver fibrosis.
    Halfon P; Munteanu M; Poynard T
    Gastroenterol Clin Biol; 2008 Sep; 32(6 Suppl 1):22-39. PubMed ID: 18973844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy.
    Park GJ; Katelaris PH; Jones DB; Seow F; Lin BP; Le Couteur DG; Ngu MC
    Aliment Pharmacol Ther; 2005 Sep; 22(5):395-403. PubMed ID: 16128677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.
    Ascione A; Ascione T; Lanza AG; Utech W; Di Costanzo GG; Macri M
    Hepatogastroenterology; 2006; 53(72):919-23. PubMed ID: 17153453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors.
    Thompson AJ; Ayres A; Yuen L; Bartholomeusz A; Bowden DS; Iser DM; Chen RY; Demediuk B; Shaw G; Bell SJ; Watson KJ; Locarnini SA; Desmond PV
    J Gastroenterol Hepatol; 2007 Jul; 22(7):1078-85. PubMed ID: 17608854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time?
    Thuluvath PJ; Krok KL
    Am J Gastroenterol; 2005 Sep; 100(9):1981-3. PubMed ID: 16128942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
    Canbakan M; Senturk H; Canbakan B; Toptas T; Tabak O; Ozaras R; Tabak F; Balcı H; Sut N; Ozbay G
    Nephron Clin Pract; 2011; 117(3):c289-95. PubMed ID: 20847572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
    Dai CY; Yu ML; Hsieh MY; Lee LP; Hou NJ; Huang JF; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
    Liver Int; 2007 Dec; 27(10):1364-70. PubMed ID: 17900250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.